Merck Stocks Rise 2.6% With Qlex Still Under 10% of Keytruda Sales
Merck (MRK) shares rose 2.6% to $150.13 after JPMorgan raised its price target to $175. Q3 sales hit $18.085B, with Keytruda and Qlex generating $8.6B (9.7% from Qlex). Keytruda accounted for 48% of total sales. MRK has a P/E ratio of 120 and a GF Score of 81/100.
How this was made
The 30-second read
Why it matters
Analyst upgrade and price target raise reflect confidence in diversification, but valuation remains stretched.
Market read
Earnings-driven move with analyst upgrade makes MRK a near‑term buying opportunity.
What to watch
High P/E of 120 suggests valuation risk despite earnings beat.
Background
Merck's Q3 earnings highlight revenue concentration in the Keytruda franchise and a modest contribution from the newer Qlex formulation.
Ticker impact
Q3 results show $8.6B from Keytruda franchise and $830M from Qlex, prompting JPMorgan price target lift and 2.6% share rise.
likely upward pressure as investors price in higher target and revenue diversification.
Fresh earnings numbers and analyst upgrade are new, material, and already moving the stock.
Market effects
Strong pharma earnings may lift peer biotech and oncology stocks.
U.S. market gains from a major health‑care name.
Limited to U.S. and global pharma investors.
Counterpoint
If Qlex cannibalizes existing Keytruda sales, growth may stall.
Key entities
- analystJPMorgan
Raised MRK price target to $175, maintaining Overweight.
